Analysts have raised their price target for Iovance Biotherapeutics from $7.75 to $8.25 per share, citing updated financial metrics and modestly adjusted long-term growth assumptions.
What's in the News
- Iovance Biotherapeutics reaffirmed its revenue guidance for the full year 2025, projecting $250 to $300 million in the first full calendar year of Amtagvi sales. (Key Developments)
- The company announced interim data from a Phase 2 IOV-LUN-202 trial of lifileucel monotherapy for previously treated advanced nonsquamous NSCLC patients, showing a 25.6% objective response rate, including two complete responses and a 71.8% disease control rate after a median 25.4 months of follow-up. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has increased from $7.75 to $8.25 per share, reflecting a modest rise in projected valuation.
- Discount Rate edged up slightly from 7.06% to 7.12%, indicating a marginal adjustment in risk assessment.
- Revenue Growth forecast remains essentially unchanged at approximately 45.6%.
- Net Profit Margin is steady at just over 9.0%, with no meaningful change from the previous estimate.
- Future P/E ratio has risen from 66.4x to 70.9x, suggesting a higher multiple is being applied to forward-looking earnings.
Have other thoughts on Iovance Biotherapeutics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.